This Truveta company profile covers the company's valuation, revenue, funding rounds, investors and history. Truveta works in healthcare, with a focus on health data and research. It was founded in 2020 and is headquartered in Bellevue, Washington, United States. Its latest valuation on record is More than US$1 billion (January 2025). Every figure links to a public source, and anything the company hasn't disclosed is marked as such.
Revenue
Funding history
| Date | Round | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jan 2025 | Series C | US$320M | More than US$1B | Seventeen health system members; Regeneron (US$119.5M upfront); Illumina (US$20M) | GeekWire |
Truveta timeline
Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.
- 2020 — Truveta is founded in Bellevue by Terry Myerson (CEO), with founding health system members.
- Jan 2025 — Series C: US$320M, valuing the company at More than US$1B. Investors: Seventeen health system members; Regeneron (US$119.5M upfront); Illumina (US$20M).
Investors
Overview
Truveta is a health data company owned in large part by US health systems. Its member health systems contribute de-identified electronic health record data, creating one of the largest and most up-to-date sources of clinical data in the United States, which researchers, pharmaceutical companies and the health systems themselves use to study diseases, treatments and outcomes. In January 2025 Truveta raised US$320 million from 17 health systems, Regeneron and Illumina at a valuation of more than US$1 billion, and launched the Truveta Genome Project, which aims to combine clinical data with genetic sequencing from millions of volunteers.
Terry Myerson founded Truveta in 2020 and serves as CEO. Myerson previously led Microsoft's Windows and Devices group as an executive vice president. Truveta was formed with a group of health systems that wanted to use their collective data to improve care and research, while keeping patient privacy protected and retaining a share in the value created.
Products
- Truveta Data: regularly updated, de-identified clinical data from member health systems, covering diagnoses, medications, labs, procedures and outcomes.
- Truveta Studio: analytics software for researchers to explore data and run studies.
- AI models: tools that structure clinical notes and other unstructured data for research.
- Truveta Genome Project: an initiative with Regeneron to sequence the exomes of up to ten million volunteers and link genetic data with clinical records.
Funding
Truveta was funded initially by its founding health system members. In January 2025 it announced a US$320 million Series C, with 17 health systems, Regeneron and Illumina investing in preferred equity at a valuation exceeding US$1 billion. Regeneron's strategic investment included US$119.5 million upfront, and Illumina committed US$20 million. GeekWire described Truveta as the Seattle region's newest unicorn.
Business model
Truveta earns revenue from selling access to its data and analytics to life sciences companies, researchers, public health agencies and health systems. Member health systems benefit from the insights and share in the company's value through ownership. The genome project creates additional value by linking genetic and clinical data for drug discovery, particularly with Regeneron.
Competition
Truveta competes with health data and real-world evidence companies such as Komodo Health, Flatiron Health (owned by Roche), IQVIA, Optum and Epic's Cosmos research database. Its distinguishing features are ownership by health systems, timely data and its genomic initiative.
Truveta at a glance
Truveta is a Bellevue, Washington, health data company founded in 2020 by former Microsoft executive Terry Myerson with health system members. It provides de-identified clinical data and analytics for research. It raised US$320 million in January 2025 from health systems, Regeneron and Illumina at a valuation of more than US$1 billion and launched the Truveta Genome Project.
Timeline
- 2020: founded with initial health system members.
- 2021–2023: launches data platform and adds members.
- January 2025: raises US$320 million at more than US$1 billion; launches genome project.
Why health systems pooled their data
Each health system holds valuable data, but on its own it represents a limited population. Combining data from many systems creates large, diverse data sets that can reveal patterns in diseases and treatments. Historically, health data companies bought data from providers and captured most of the value. Truveta's member-owned model lets health systems share in the economics and govern how data is used, while research benefits from timely, broad data.
Privacy and governance
Using patient data for research requires strong privacy protections. Truveta uses de-identified data under rules such as HIPAA, with governance by member health systems. The genome project involves volunteers who consent to sequencing. Public trust depends on transparency about how data is used and protected, and health data companies face scrutiny from regulators and privacy advocates.
Who funds Truveta
Truveta's owners and investors include its member health systems, such as Providence, Advocate Health, Trinity Health and Tenet Healthcare, along with strategic investors Regeneron and Illumina.
Who uses Truveta
Truveta's customers include pharmaceutical and biotech companies, academic researchers, public health agencies and its member health systems.
Valuation context
Truveta's valuation of more than US$1 billion reflects the value of large, timely clinical data sets for research and AI. Our guide to health tech unicorns compares it with peers.
Risks
- Privacy regulation: changes in health data rules could limit use.
- Member alignment: health systems must continue to contribute data.
- Competition: large incumbents offer similar data.
Questions for researchers
- How current and complete is the data for your research question?
- How is data de-identified and governed?
- What analytics and support are available?
How researchers use Truveta
A pharmaceutical company studying a new drug's safety after approval might use Truveta to identify patients who received it, compare their outcomes with similar patients on other treatments and look for rare side effects across millions of records. Because Truveta's data is refreshed frequently from health systems' electronic records, researchers can study recent trends, such as the effects of newly approved medications or emerging infections, faster than with older data sources. Truveta's AI tools convert unstructured information, such as clinical notes, into structured data, making analyses more complete. Public health researchers have used similar data to study vaccine uptake, disease patterns and health disparities.
The genome project adds another dimension. Linking genetic information to detailed medical histories can help identify genes associated with diseases or drug responses, which can guide drug discovery and personalised medicine.
Health system ownership in practice
Truveta's member health systems include large non-profit and for-profit hospital operators across many states. Each contributes data and participates in governance, deciding how data may be used and which research uses are appropriate. This differs from traditional data brokers, which buy data and set their own policies. Members benefit through their equity stakes and through access to insights from the combined data set, which can help them improve care quality and operations.
Researchers considering Truveta should compare its coverage with other data sources for their specific populations and questions.
Timeliness and governance are usually its main selling points to research customers.
Members can also apply the combined data to their own quality improvement work.
Latest developments (October 2026)
Truveta added Erik Wexler, chief executive of Providence, to its board in March 2026. Its January 2025 Series C of US$320 million, which funded a genome project with Regeneron, remains its latest financing, according to FundedIQ. The health-data company is owned in part by the health systems that contribute records. See our health tech unicorns guide.
What to watch
Watch genome project enrolment, new members, pharmaceutical partnerships and AI products.
Takeaways
Researchers gain access to large, timely clinical data. Health systems share in the value of their data. Investors should watch privacy and governance.
Sources
Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.
Frequently asked questions
What does Truveta do?
Truveta is a healthcare / health data and research company headquartered in Bellevue, Washington, United States. It was founded in 2020.
What is Truveta's valuation?
Truveta was valued at More than US$1 billion as of January 2025, according to GeekWire. Private company valuations are set at funding rounds or share sales and can change significantly between them.
How much revenue does Truveta make?
Truveta is a private company and has not publicly disclosed its revenue. Figures on third-party sites are usually modelled estimates rather than numbers reported by the company.
What was Truveta's latest funding round?
The most recent financing we have verified is a series c in Jan 2025: US$320M, at a valuation of More than US$1B. Source: GeekWire.
Who are Truveta's investors?
Investors named in public announcements include Regeneron, Illumina, Providence, Advocate Health, Trinity Health and Tenet Healthcare.
Who founded Truveta?
Truveta was founded in 2020 by Terry Myerson (CEO), with founding health system members.
Is Truveta a public company?
No. Truveta is a private company (private, venture backed), so its shares are not traded on a stock exchange and it isn't required to publish its financial results.
Where is Truveta headquartered?
Truveta is headquartered in Bellevue, Washington, United States.